Cerus (NASDAQ:CERS) Upgraded by Wall Street Zen to Buy Rating

Key Points

• Cerus (NASDAQ:CERS) was upgraded by Wall Street Zen from "hold" to "buy", joining BTIG and leaving the stock with two Buy and two Sell analyst ratings and a consensus price target of $4.00 (market consensus remains "Hold").
• Q1 results beat expectations with revenue of $59.9M and EPS of -$0.01 (better than estimates) and positive operating cash flow, but the company guided FY2026 revenue to $227.0M–$231.0M, slightly below consensus and potentially capping upside.
• Significant insider selling has occurred recently (about 1.19M shares worth ~$2.1M over 90 days), which, alongside mixed institutional flows, may weigh on investor sentiment despite improving financials.

Cerus (NASDAQ:CERS - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday.

Other analysts have also recently issued research reports about the stock. Zacks Research cut shares of Cerus from a "hold" rating to a "strong sell" rating in a research report on Thursday, March 12th. TD Cowen restated a "buy" rating on shares of Cerus in a research report on Monday, January 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Cerus in a research report on Wednesday, March 25th. Finally, BTIG Research upgraded shares of Cerus from a "neutral" rating to a "buy" rating and set a $4.00 target price on the stock in a research report on Friday. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $4.00.

Cerus Stock Performance

NASDAQ CERS opened at $2.72 on Friday. Cerus has a 1 year low of $1.15 and a 1 year high of $3.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.73 and a quick ratio of 1.17. The stock has a market capitalization of $545.01 million, a PE ratio of -34.00 and a beta of 1.62. The company's 50 day simple moving average is $1.97 and its two-hundred day simple moving average is $1.98.

Cerus (NASDAQ:CERS - Get Free Report) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.63%. The business had revenue of $59.89 million for the quarter, compared to analysts' expectations of $55.68 million. Analysts predict that Cerus will post -0.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Kevin Dennis Green sold 127,544 shares of Cerus stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $1.66, for a total value of $211,723.04. Following the transaction, the chief financial officer owned 1,040,551 shares in the company, valued at $1,727,314.66. This trade represents a 10.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Chrystal Jensen sold 30,845 shares of Cerus stock in a transaction on Friday, March 6th. The stock was sold at an average price of $2.01, for a total transaction of $61,998.45. Following the completion of the transaction, the insider owned 1,059,139 shares in the company, valued at approximately $2,128,869.39. The trade was a 2.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,194,282 shares of company stock worth $2,106,290 over the last 90 days. Insiders own 5.60% of the company's stock.

Hedge Funds Weigh In On Cerus

A number of large investors have recently added to or reduced their stakes in CERS. Cibc World Markets Corp bought a new stake in Cerus in the 4th quarter worth $25,000. MML Investors Services LLC bought a new stake in Cerus in the 4th quarter worth $37,000. Caitong International Asset Management Co. Ltd grew its holdings in Cerus by 68.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company's stock worth $39,000 after acquiring an additional 7,603 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Cerus in the 1st quarter worth $35,000. Finally, Bingham Private Wealth LLC bought a new stake in Cerus in the 4th quarter worth $40,000. Hedge funds and other institutional investors own 78.37% of the company's stock.

Cerus News Summary

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Q1 results beat expectations: revenue rose ~22.6% YoY to $59.9M and diluted EPS was -$0.01, beating estimates — the top‑line beat and narrower loss are being cited as the primary catalyst lifting the stock. QuiverQuant: Q1 2026 Earnings
• Positive Sentiment: Analyst upgrade: BTIG Research raised CERS from "neutral" to "buy" with a $4.00 price target (material upside to the current level), which can attract momentum buyers and fresh coverage. The Fly / BTIG upgrade
• Positive Sentiment: Improving profitability & cash flow: operating loss narrowed substantially vs. last year, net loss fell sharply, and operating cash flow was positive ($6.2M); these trends reduce near‑term funding pressure. QuiverQuant: financial details
• Neutral Sentiment: Detailed context is available in the earnings call/transcripts for investors who want management color on growth drivers and timing. Seeking Alpha Transcript
• Neutral Sentiment: Small government contract receipts and mixed institutional flows: some large funds added positions while others reduced holdings — signals of both conviction and rotation into/out of the name. QuiverQuant: institutional & contract data
• Negative Sentiment: FY2026 revenue guidance was updated to $227.0M–$231.0M, which sits below consensus (~$233.9M) — the guide shortfall may cap upside if investors focus on FY outlook rather than the quarterly beat. MarketBeat: guidance note
• Negative Sentiment: Significant insider selling over recent months is a red flag for some investors and may weigh on sentiment despite improving results. QuiverQuant: insider trades

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.